SARS
MCID: SVR001
MIFTS: 68

Severe Acute Respiratory Syndrome (SARS)

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Severe Acute Respiratory Syndrome

MalaCards integrated aliases for Severe Acute Respiratory Syndrome:

Name: Severe Acute Respiratory Syndrome 12 73 20 58 29 3 44 15 17 70
Sars 12 20 58 3
Sars-Cov Infection 12
Sar Deficiency 6
Sars-1 58

Characteristics:

Orphanet epidemiological data:

58
severe acute respiratory syndrome
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:2945
ICD9CM 34 079.82
MeSH 44 D045169
NCIt 50 C85064
SNOMED-CT 67 398447004
ICD10 32 J12.81 U04 U04.9
MESH via Orphanet 45 D045169
ICD10 via Orphanet 33 U04.9
UMLS via Orphanet 71 C1175175
Orphanet 58 ORPHA140896
UMLS 70 C1175175

Summaries for Severe Acute Respiratory Syndrome

CDC : 3 Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. The illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained. Since 2004, there have not been any known cases of SARS reported anywhere in the world. The content in this website was developed for the 2003 SARS epidemic. But some guidelines are still being used. Any new SARS updates will be posted on this website.

MalaCards based summary : Severe Acute Respiratory Syndrome, also known as sars, is related to disease by infectious agent and middle east respiratory syndrome, and has symptoms including fever, headache and dry cough. An important gene associated with Severe Acute Respiratory Syndrome is BSG (Basigin (Ok Blood Group)), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Montelukast and Bromhexine have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, kidney and liver, and related phenotypes are cough and fever

Disease Ontology : 12 A Coronavirus infection that results in infection located in respiratory tract, has material basis in SARS coronavirus (SARS-CoV), which is transmitted by droplet spread of respiratory secretions, transmitted by ingestion of contaminated food, or transmitted by fomites. The infection has symptom fever, has symptom headache, has symptom body aches, has symptom dry cough, and has symptom hypoxia.

Wikipedia : 73 Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by... more...

Related Diseases for Severe Acute Respiratory Syndrome

Diseases in the Respiratory Failure family:

Severe Acute Respiratory Syndrome

Diseases related to Severe Acute Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1230)
# Related Disease Score Top Affiliating Genes
1 disease by infectious agent 31.4 TNF IL1B IFNB1 IFNA1 CRP CLEC4M
2 middle east respiratory syndrome 31.3 TMPRSS2 IRF3 IFNB1 CXCL10 CTSL ACE2
3 respiratory failure 31.1 TNF IL1B CXCL8 CXCL10 CRP CCL5
4 pneumonia 31.1 TNF IL1B CXCL8 CXCL10 CRP CCL5
5 myocarditis 31.0 TNF IL1B IFNA1 CCL2
6 kawasaki disease 30.9 TNF IL1B CRP CCL2
7 pulmonary edema 30.9 TNF IL1B CXCL8 CRP
8 bronchopneumonia 30.9 TNF IL1B CXCL8 CRP
9 orchitis 30.8 TNF IL1B CRP ACE2
10 post-traumatic stress disorder 30.8 IL1B CRP CCL2
11 avian influenza 30.8 TNF IFNA1 DDX58 CXCL8 CXCL10
12 gastroenteritis 30.8 TNF IL1B IFNA1 CXCL8 CRP
13 pustulosis of palm and sole 30.8 TNF CXCL8 CRP
14 common cold 30.8 TNF IL1B CXCL8 CCL5 ACE2
15 covid-19 30.7 TMPRSS2 IL1B IFNB1 IFNA1 CXCL8 CXCL10
16 bacterial pneumonia 30.7 TNF IL1B CXCL8 CRP
17 bronchiectasis 30.7 TNF IL1B CXCL8 CRP
18 conjunctivitis 30.7 TNF CXCL8 CCL2
19 tetanus 30.7 TNF IL1B HLA-A CRP
20 subacute thyroiditis 30.7 TNF IL1B CRP
21 pericarditis 30.7 TNF IL1B CXCL8 CRP
22 vaccinia 30.6 TNF IRF3 IFNB1 IFNA1
23 stevens-johnson syndrome/toxic epidermal necrolysis 30.6 HLA-C HLA-A
24 chronic kidney disease 30.6 TNF IL1B HLA-A CRP CCL2 ACE2
25 bronchitis 30.6 TNF IL1B CXCL8 CXCL10 CRP CCL5
26 dengue virus 30.6 TNF DDX58 CD209
27 diarrhea 30.6 TNF IL1B IFNB1 IFNA1 CXCL8
28 acquired immunodeficiency syndrome 30.6 TNF IL1B IFNA1 CRP
29 bronchiolitis obliterans 30.6 TNF CXCL8 CRP
30 cryptogenic organizing pneumonia 30.5 TNF CXCL8 CRP
31 lung disease 30.5 TNF IL1B CXCL8 CXCL10 CRP CCL5
32 thyroiditis 30.5 TNF IL1B IFNA1 CXCL10 CRP
33 ulcerative colitis 30.5 TNF IL1B CXCL8 CRP
34 meningoencephalitis 30.5 TNF CXCL10 CRP CCL5
35 neutropenia 30.5 TNF IL1B IFNA1 CXCL8 CRP
36 chlamydia pneumonia 30.5 TNF IL1B CXCL8 CRP CCL2
37 chlamydia 30.5 TNF IL1B CXCL8 CRP CCL2
38 west nile virus 30.5 IRF3 IFNA1 DDX58 CLEC4M CD209
39 mycobacterium tuberculosis 1 30.5 TNF IFNB1 CXCL10 CD209
40 pre-eclampsia 30.5 TNF IL1B HLA-C CXCL8 CRP
41 macrophage activation syndrome 30.5 TNF CRP ACE2
42 bone resorption disease 30.5 TNF IL1B CRP
43 stomatitis 30.5 TNF IL1B IFNB1 IFNA1 DDX58 CXCL8
44 venezuelan equine encephalitis 30.5 IFNB1 IFNA1 CXCL10 CCL2
45 haemophilus influenzae 30.5 TNF CXCL8
46 chickenpox 30.4 TNF IFNB1 IFNA1 CRP
47 hemophagocytic lymphohistiocytosis 30.4 TNF CXCL8 CCL5 CCL2
48 hepatitis a 30.4 TNF IL1B IFNA1
49 dengue disease 30.4 TNF IFNB1 IFNA1 CD209 CCL5
50 acute pancreatitis 30.4 TNF IL1B CXCL8 CRP

Graphical network of the top 20 diseases related to Severe Acute Respiratory Syndrome:



Diseases related to Severe Acute Respiratory Syndrome

Symptoms & Phenotypes for Severe Acute Respiratory Syndrome

Human phenotypes related to Severe Acute Respiratory Syndrome:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cough 58 31 hallmark (90%) Very frequent (99-80%) HP:0012735
2 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
3 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
4 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
5 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
6 respiratory distress 58 31 frequent (33%) Frequent (79-30%) HP:0002098
7 diabetes mellitus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000819
8 abnormality of the cardiovascular system 58 31 occasional (7.5%) Occasional (29-5%) HP:0001626
9 neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0002664
10 respiratory failure requiring assisted ventilation 58 31 occasional (7.5%) Occasional (29-5%) HP:0004887
11 hypoxemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012418
12 chronic lung disease 58 31 occasional (7.5%) Occasional (29-5%) HP:0006528
13 pharyngitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0025439
14 acute infectious pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011949
15 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
16 dyspnea 58 Frequent (79-30%)

Symptoms:

12
  • fever
  • headache
  • dry cough
  • body aches
  • hypoxia

UMLS symptoms related to Severe Acute Respiratory Syndrome:


fever; pruritus; snoring; coughing

MGI Mouse Phenotypes related to Severe Acute Respiratory Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 ACE2 BSG CCL5 CD209 CLEC4M CXCL10
2 immune system MP:0005387 9.47 ACE2 BSG CCL2 CCL5 CLEC4M CRP

Drugs & Therapeutics for Severe Acute Respiratory Syndrome

Drugs for Severe Acute Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 535)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Bromhexine Approved Phase 4 3572-43-8
3
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
4
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
5
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
6
Cetirizine Approved Phase 4 83881-51-0 2678
7
Levocetirizine Approved Phase 4 130018-77-8 1549000
8
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
9
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
10
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
11
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
12
Zinc Approved, Investigational Phase 4 7440-66-6 32051
13
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
14
Coal tar Approved Phase 4 8007-45-2
15
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
16
Copper Approved, Investigational Phase 4 7440-50-8 27099
17
Budesonide Approved Phase 4 51333-22-3 63006 5281004
18
Ibuprofen Approved Phase 4 15687-27-1 3672
19
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
20
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
21
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
22
Eprosartan Approved Phase 4 133040-01-4 5281037
23
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
BCG vaccine Approved, Investigational Phase 4
26
Rivaroxaban Approved Phase 4 366789-02-8
27
Povidone Approved Phase 4 9003-39-8 131751496
28
Povidone-iodine Approved Phase 4 25655-41-8
29
Iodine Approved, Investigational Phase 4 7553-56-2 807
30
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
31
Linagliptin Approved Phase 4 668270-12-0 10096344
32
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
34
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
36
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
37
Tranilast Investigational Phase 4 53902-12-8 93543
38
Candesartan Experimental Phase 4 139481-59-7 2541
39
Cadexomer iodine Experimental Phase 4 94820-09-4
40 Bronchodilator Agents Phase 4
41 Pharmaceutical Solutions Phase 4
42 Anti-Asthmatic Agents Phase 4
43 Respiratory System Agents Phase 4
44 Platelet Aggregation Inhibitors Phase 4
45 Hormone Antagonists Phase 4
46 Anti-Inflammatory Agents Phase 4
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48 Dermatologic Agents Phase 4
49 Cholinergic Agents Phase 4
50 Leukotriene Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 1844)
# Name Status NCT ID Phase Drugs
1 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Completed NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
2 Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts Completed NCT04652648 Phase 4 Hydroxychloroquine
3 GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study Completed NCT04473274 Phase 4 Pioglitazone
4 A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection Completed NCT04252885 Phase 4 Lopinavir and Ritonavir Tablets;Arbidol
5 A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04621461 Phase 4 Placebo
6 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial Completed NCT04405999 Phase 4 Bromhexine Hydrochloride
7 Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial Completed NCT04353596 Phase 4 ACE inhibitor, angiotensin receptor blocker
8 Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients Completed NCT04739410 Phase 4 Ivermectin
9 An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
10 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
11 A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Using Subjective and Objective Measures to Evaluate the Clinical Efficacy of Mometasone Furoate Nasal Spray (MFNS) Following Initial and Maintenance Dosing in Subjects With Allergen-Induced Seasonal Allergic Rhinitis (SAR) in an Environmental Exposure Chamber (EEC) Completed NCT00491504 Phase 4 Mometasone Furoate Nasal Spray
12 Double-blind, Three Parallel Randomized Groups, Therapeutic Confirmatory Clinical Trial to Compare the Efficacy of Oral Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU) Completed NCT00295022 Phase 4 Placebo;Montelukast;Levocetirizine
13 A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen Completed NCT00160537 Phase 4 Levocetirizine
14 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma Completed NCT00070707 Phase 4 Mometasone;Placebo;Albuterol/Salbutamol
15 A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) Completed NCT00783211 Phase 4 desloratadine;fexofenadine;placebo
16 A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) Completed NCT00783146 Phase 4 desloratadine;fexofenadine;placebo
17 Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Completed NCT02932774 Phase 4 Cetirizine;Loratadine
18 A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen Completed NCT00867191 Phase 4 Placebo;Desloratadine
19 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
20 A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius. Completed NCT00805584 Phase 4 desloratadine
21 Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR) Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
22 National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines Recruiting NCT04760132 Phase 4
23 Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection Recruiting NCT04340557 Phase 4 Losartan
24 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Recruiting NCT04414267 Phase 4
25 MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection Recruiting NCT04780581 Phase 4 Dexamethasone;Methylprednisolone
26 Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses Recruiting NCT04348370 Phase 4
27 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Recruiting NCT04335786 Phase 4 Valsartan (Diovan);Placebo oral tablet
28 Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2) Recruiting NCT04530578 Phase 4 Heparin sodium;Enoxaparin
29 A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Recruiting NCT04639375 Phase 4
30 COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study: an Open-label Randomized Controlled Trial Recruiting NCT04746430 Phase 4 Dexamethasone
31 Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia Recruiting NCT04355637 Phase 4 Inhaled budesonide
32 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Recruiting NCT04334629 Phase 4 Ibuprofen
33 Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Recruiting NCT04530448 Phase 4 Sodium bicarbonate
34 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Recruiting NCT04394117 Phase 4 Angiotensin Receptor Blockers
35 The Efficacy of Pre-procedural Mouth Rinses on SARS-CoV-2 Saliva Viral Load: A Randomized Control Clinical Trial Recruiting NCT04721457 Phase 4 Distilled Water;1% Povidone Iodine (PVP-I);1.5% Hydrogen Peroxide (H2O2);0.075% Cetylpyridinium Chloride (CPC);0.1% Sodium Hypochlorite
36 Pilot Study of Safety and Efficacy of Nitazoxanide in Post-exposure Prophylaxis in Household Contacts of Patients With Confirmed SARS-CoV-2 Infection Recruiting NCT04788407 Phase 4 Nitazoxanide;Placebo
37 A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection Recruiting NCT04705831 Phase 4 Ruconest
38 Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection Recruiting NCT04435587 Phase 4 Ivermectin Pill;Combined ART/hydroxychloroquine
39 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVIV) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4) Recruiting NCT04790851 Phase 4
40 Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias Recruiting NCT04552951 Phase 4 Cholecalciferol
41 Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection Active, not recruiting NCT04316377 Phase 4 Hydroxychloroquine Sulfate
42 Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial Active, not recruiting NCT04394377 Phase 4 Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed;Group 2: control group with enoxaparin 40mg/d
43 Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection Active, not recruiting NCT04411667 Phase 4 Octagam
44 Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial Active, not recruiting NCT04417335 Phase 4
45 Prospective Study in a Single Center to Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients Not yet recruiting NCT04801667 Phase 4
46 Pilot Study of the Use of IVIG in Patients With Severe COVID-19 Infections Requiring Mechanical Ventilation and to Assess Their Biological Responses to IVIG Therapy Not yet recruiting NCT04616001 Phase 4 IVIG
47 Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes Not yet recruiting NCT04341935 Phase 4 Linagliptin;Insulin regimen
48 A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years Not yet recruiting NCT04801888 Phase 4
49 A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19 Not yet recruiting NCT04517188 Phase 4 Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
50 Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection Not yet recruiting NCT04330495 Phase 4 Hidroxicloroquina;Control group

Search NIH Clinical Center for Severe Acute Respiratory Syndrome

Cochrane evidence based reviews: severe acute respiratory syndrome

Genetic Tests for Severe Acute Respiratory Syndrome

Genetic tests related to Severe Acute Respiratory Syndrome:

# Genetic test Affiliating Genes
1 Severe Acute Respiratory Syndrome 29

Anatomical Context for Severe Acute Respiratory Syndrome

The Foundational Model of Anatomy Ontology organs/tissues related to Severe Acute Respiratory Syndrome:

19
Respiratory Tract

MalaCards organs/tissues related to Severe Acute Respiratory Syndrome:

40
Kidney, Liver, Heart, Brain, T Cells, Endothelial, Eye

Publications for Severe Acute Respiratory Syndrome

Articles related to Severe Acute Respiratory Syndrome:

(show top 50) (show all 36242)
# Title Authors PMID Year
1
Mutations in the sarcosine dehydrogenase gene in patients with sarcosinemia. 6
22825317 2012
2
SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. 61
33372854 2021
3
Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading? 61
33491531 2021
4
SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay. 61
33306459 2021
5
The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. 61
33560940 2021
6
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. 61
33399524 2021
7
Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. 61
33585826 2021
8
Novel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus using the BD MAX open system. 61
33410371 2021
9
A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners. 61
33317424 2021
10
Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. 61
33704002 2021
11
Experimental re-infected cats do not transmit SARS-CoV-2. 61
33704016 2021
12
In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches. 61
33685335 2021
13
The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract. 61
33691601 2021
14
Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. 61
33538646 2021
15
Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. 61
33430659 2021
16
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 61
33095083 2021
17
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. 61
33522893 2021
18
COVID-19 evolution during the pandemic - Implications of new SARS-CoV-2 variants on disease control and public health policies. 61
33494661 2021
19
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. 61
33666147 2021
20
Immune dysregulation and system pathology in COVID-19. 61
33757410 2021
21
CPMPARISON between COVID-19 and MERS demographic data in Saudi Arabia: a retrospective study. 61
33797350 2021
22
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. 61
33734013 2021
23
Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. 61
33635184 2021
24
Evaluation of a comprehensive pre-procedural screening protocol for COVID-19 in times of a high SARS CoV-2 prevalence: a prospective cross-sectional study. 61
33583292 2021
25
Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. 61
33491498 2021
26
Epidemiological investigation of a COVID-19 family cluster outbreak transmitted by a 3-month-old infant. 61
33489103 2021
27
A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. 61
33555988 2021
28
Virus-associated ribozymes and nano carriers against COVID-19. 61
33645342 2021
29
Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. 61
33620016 2021
30
Relation between insulin growth factor 1 and survival after SARS-CoV-2(COVID 19) infection in elderly kidney transplant recipients. 61
33627041 2021
31
Susceptibility of rabbits to SARS-CoV-2. 61
33356979 2021
32
Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. 61
33407005 2021
33
Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France. 61
33399033 2021
34
Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. 61
33491508 2021
35
The cardiovascular aspect of COVID-19. 61
33345626 2021
36
The interplay between emerging human coronavirus infections and autophagy. 61
33399028 2021
37
SARS-CoV-2 and self-medication in Cameroon: a mathematical model. 61
33538240 2021
38
Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT). 61
32808808 2021
39
Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein. 61
33525998 2021
40
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. 61
33220855 2021
41
A case of peritoneal dialysis in which SARS-CoV-2 was diagnosed by sudden hearing loss. 61
33550902 2021
42
Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. 61
33171096 2021
43
Can povidone iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update. 61
33747261 2021
44
SARS-CoV-2 associated viral encephalitis with mortality outcome. 61
33654659 2021
45
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. 61
33762883 2021
46
In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis. 61
33681482 2021
47
SUMO pathway, blood coagulation and oxidative stress in SARS-CoV-2 infection. 61
33558851 2021
48
Uncertainties in estimating SARS-CoV-2 prevalence by wastewater-based epidemiology. 61
33642938 2021
49
Variations in Orf3a protein of SARS-CoV-2 alter its structure and function. 61
33527091 2021
50
Modeling airborne pathogen transport and transmission risks of SARS-CoV-2. 61
33642664 2021

Variations for Severe Acute Respiratory Syndrome

ClinVar genetic disease variations for Severe Acute Respiratory Syndrome:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SARDH NM_001134707.2(SARDH):c.211G>T (p.Val71Phe) SNV Affects 39448 rs397514504 GRCh37: 9:136599085-136599085
GRCh38: 9:133733963-133733963
2 SARDH NM_001134707.2(SARDH):c.860C>T (p.Pro287Leu) SNV Affects 39449 rs149481147 GRCh37: 9:136594942-136594942
GRCh38: 9:133729820-133729820
3 SARDH NM_001134707.2(SARDH):c.2167C>T (p.Arg723Ter) SNV Affects 39450 rs149391396 GRCh37: 9:136536816-136536816
GRCh38: 9:133671694-133671694
4 SARDH NM_001134707.2(SARDH):c.1540C>T (p.Arg514Ter) SNV Affects 39451 rs140559739 GRCh37: 9:136570084-136570084
GRCh38: 9:133704962-133704962

Expression for Severe Acute Respiratory Syndrome

Search GEO for disease gene expression data for Severe Acute Respiratory Syndrome.

Pathways for Severe Acute Respiratory Syndrome

Pathways related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNF IRF3 IL1B IFNB1 IFNA1 HLA-C
2
Show member pathways
13.85 TNF TMPRSS2 IRF3 IL1B IFNB1 IFNA1
3
Show member pathways
13.26 TNF IRF3 IL1B IFNB1 IFNA1 HLA-C
4
Show member pathways
13.19 TNF IRF3 IL1B IFNB1 IFNA1 DDX58
5
Show member pathways
13.01 TNF IRF3 IFNB1 IFNA1 HLA-C HLA-A
6
Show member pathways
12.9 TNF IL1B IFNA1 HLA-C HLA-A CXCL8
7
Show member pathways
12.82 TNF IRF3 IL1B IFNB1 IFNA1 HLA-C
8
Show member pathways
12.77 TNF IRF3 IL1B IFNB1 IFNA1 CXCL8
9
Show member pathways
12.61 IRF3 IL1B IFNB1 IFNA1 DDX58 CXCL10
10
Show member pathways
12.59 IRF3 IFNB1 IFNA1 HLA-C HLA-A DDX58
11
Show member pathways
12.59 TNF IRF3 IFNB1 IFNA1 DDX58 CXCL8
12
Show member pathways
12.55 TNF IFNB1 IFNA1 HLA-C HLA-A
13 12.55 TNF IRF3 IL1B IFNB1 IFNA1 HLA-C
14 12.52 TNF IRF3 IL1B IFNA1 DDX58 CXCL10
15 12.46 TNF IRF3 IL1B IFNB1 CXCL8 CCL5
16
Show member pathways
12.39 TNF IL1B CXCL8 CXCL10 CCL2
17
Show member pathways
12.38 TNF CXCL8 CXCL10 CCL5 CCL2
18
Show member pathways
12.38 TNF IL1B CRP CCL5 CCL2
19 12.32 TNF IL1B IFNB1 IFNA1 CLEC4M CD209
20
Show member pathways
12.31 TNF IRF3 IL1B CXCL8
21
Show member pathways
12.28 TNF IRF3 IFNB1 CXCL8
22
Show member pathways
12.27 TNF IRF3 IL1B IFNB1 IFNA1 HLA-C
23
Show member pathways
12.23 TNF IL1B CLEC4M CD209
24
Show member pathways
12.23 TNF IL1B IFNB1 CXCL8 CXCL10 CTSL
25
Show member pathways
12.22 TNF IL1B IFNB1 IFNA1
26
Show member pathways
12.21 TNF TMPRSS2 IRF3 IL1B IFNB1 IFNA1
27 12.2 HLA-C HLA-A CTSL CLEC4M CD209
28 12.13 TNF IL1B CTSL CCL2
29 12.12 TNF IRF3 IL1B IFNB1 CXCL8 CCL2
30 12.08 TNF IL1B CXCL8 CXCL10 CCL2
31 12.03 TNF IL1B CXCL8 CCL2
32 12 TNF IL1B IFNB1 CXCL10 CCL5 CCL2
33 11.99 TNF IL1B DDX58 CXCL8
34 11.96 TNF IL1B CXCL8 CCL2
35 11.88 TNF IL1B CXCL8 CTSL CCL5 CCL2
36 11.82 TNF IRF3 IL1B CXCL8
37 11.82 TNF IRF3 IL1B IFNB1 IFNA1 CXCL8
38 11.8 TNF IL1B IFNB1 CD209
39 11.72 TNF IL1B CXCL8 CCL5 CCL2
40
Show member pathways
11.68 TNF IL1B CXCL8
41 11.63 TNF IL1B CXCL8
42 11.61 TNF IL1B CXCL8 CCL2
43 11.55 TNF IL1B CCL2
44 11.43 IL1B IFNB1 CXCL10
45 11.42 TNF IL1B CXCL8 CXCL10 CCL5 CCL2
46 11.31 TNF IL1B IFNB1
47 11.26 TNF IFNB1 CXCL8 CCL5
48 11.1 TNF CXCL8 CRP
49 11.06 TNF IL1B CXCL8 CXCL10 CCL5 CCL2
50 11.01 TNF IL1B CCL2

GO Terms for Severe Acute Respiratory Syndrome

Cellular components related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 TNF IL1B IFNB1 IFNA1 CXCL8 CXCL10
2 extracellular region GO:0005576 9.47 TNF TMPRSS2 IL1B IFNB1 IFNA1 CXCL8
3 MHC class I protein complex GO:0042612 9.16 HLA-C HLA-A

Biological processes related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.17 IRF3 HLA-C HLA-A DDX58 CLEC4M CD209
2 innate immune response GO:0045087 10.13 IRF3 HLA-C HLA-A DDX58 CRP CLEC4M
3 positive regulation of gene expression GO:0010628 10.1 TNF IL1B DDX58 CXCL8 CRP
4 adaptive immune response GO:0002250 10.08 IFNB1 IFNA1 HLA-C HLA-A CTSL CLEC4M
5 viral process GO:0016032 10.03 IRF3 HLA-C HLA-A DDX58 CLEC4M CD209
6 inflammatory response GO:0006954 10.02 TNF IL1B CXCL8 CXCL10 CRP CCL5
7 defense response to virus GO:0051607 10 IRF3 IFNB1 IFNA1 DDX58 CXCL10
8 chemotaxis GO:0006935 9.96 CXCL8 CXCL10 CCL5 CCL2
9 defense response GO:0006952 9.96 TNF IFNB1 IFNA1 CXCL8 CXCL10
10 positive regulation of interleukin-6 production GO:0032755 9.91 TNF IL1B DDX58 BSG
11 response to virus GO:0009615 9.91 TNF IFNB1 DDX58 CXCL10 CCL5
12 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CXCL10 CCL5 CCL2
13 cellular response to interleukin-1 GO:0071347 9.88 CXCL8 CCL5 CCL2
14 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B CCL5 CCL2
15 regulation of insulin secretion GO:0050796 9.87 TNF IL1B CCL5
16 interferon-gamma-mediated signaling pathway GO:0060333 9.87 IRF3 HLA-C HLA-A
17 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL1B HLA-A
18 positive regulation of T cell proliferation GO:0042102 9.85 IL1B CD209 CCL5
19 positive regulation of interleukin-8 production GO:0032757 9.85 TNF IL1B DDX58
20 humoral immune response GO:0006959 9.85 TNF IFNB1 IFNA1 CCL2
21 viral entry into host cell GO:0046718 9.85 CTSL CLEC4M CD209 BSG ACE2
22 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IRF3 IL1B CXCL8 CXCL10 CCL2
23 negative regulation of viral genome replication GO:0045071 9.83 TNF IFNB1 CCL5
24 protein kinase B signaling GO:0043491 9.83 TNF IL1B CCL5 CCL2
25 cellular response to fibroblast growth factor stimulus GO:0044344 9.8 CXCL8 CCL5 CCL2
26 response to exogenous dsRNA GO:0043330 9.8 IRF3 IFNB1 IFNA1 DDX58
27 neutrophil chemotaxis GO:0030593 9.8 CXCL8 CXCL10 CCL5 CCL2 BSG
28 leukocyte cell-cell adhesion GO:0007159 9.79 CLEC4M CD209 CCL5
29 cellular response to exogenous dsRNA GO:0071360 9.77 IRF3 IFNB1 DDX58
30 viral genome replication GO:0019079 9.74 CLEC4M CD209 CCL2
31 type I interferon signaling pathway GO:0060337 9.72 IRF3 IFNB1 IFNA1 HLA-C HLA-A
32 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL1B
33 positive regulation of viral entry into host cell GO:0046598 9.71 TMPRSS2 BSG
34 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
35 negative regulation of lipid storage GO:0010888 9.69 TNF CRP
36 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.69 HLA-C HLA-A
37 modulation by virus of host morphology or physiology GO:0019048 9.68 CLEC4M CD209
38 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.68 HLA-C HLA-A
39 vascular endothelial growth factor production GO:0010573 9.67 TNF IL1B
40 cell-cell recognition GO:0009988 9.67 CLEC4M CD209
41 positive regulation of fever generation GO:0031622 9.66 TNF IL1B
42 virion attachment to host cell GO:0019062 9.66 CLEC4M CD209
43 sequestering of triglyceride GO:0030730 9.65 TNF IL1B
44 antigen processing and presentation GO:0019882 9.65 HLA-C HLA-A CTSL CLEC4M CD209
45 macrophage apoptotic process GO:0071888 9.64 IRF3 CTSL
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 TNF IL1B
47 peptide antigen transport GO:0046968 9.63 CLEC4M CD209
48 positive regulation of cellular biosynthetic process GO:0031328 9.63 CXCL8 CCL5
49 immune response GO:0006955 9.61 TNF IL1B HLA-C HLA-A CXCL8 CXCL10
50 lipopolysaccharide-mediated signaling pathway GO:0031663 9.55 TNF IRF3 IL1B CCL5 CCL2

Molecular functions related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.4 TNF TMPRSS2 SH2D3A IRF3 IL1B IFNB1
2 virus receptor activity GO:0001618 9.62 CLEC4M CD209 BSG ACE2
3 mannose binding GO:0005537 9.54 CLEC4M CD209 BSG
4 chemokine activity GO:0008009 9.46 CXCL8 CXCL10 CCL5 CCL2
5 TAP binding GO:0046977 9.43 HLA-C HLA-A
6 virion binding GO:0046790 9.43 CRP CLEC4M CD209
7 peptide antigen binding GO:0042605 9.26 HLA-C HLA-A CLEC4M CD209
8 cytokine activity GO:0005125 9.23 TNF IL1B IFNB1 IFNA1 CXCL8 CXCL10

Sources for Severe Acute Respiratory Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....